Home >> Industry News >> All The News
sideview vmo3D sideview vmo3D 30 day free trial
  • Also available via:

Boy recovers completely after key in eye PDF
Submit Your News
Feature Story
Thursday, 27 November 2008
Nicholas Holderman, like any young boy, is playful, energetic and talkative but on September 2, that changed in the blink of an eye. Nicholas fell down and the parents heard him cry. What they didn't know just yet was their 17-month-old son Nicholas had the key to their car, which he fell on. The key went through his eyelid, into his eye and even to his brain (see picture).

For six days, Nicholas was at University of Kentucky hospital, his parents and brothers by his side praying for his recovery. They were told his eye was ruptured, before another team of specialists looked at it again and found nothing wrong with him.

More than two months later, Nicholas Holderman has recovered. He’s now considered a miracle to not only his family, but to the community.
Delcath Systems Granted Orphan-Drug Designations for Cutaneous and Ocular Melanoma PDF
Submit Your News
Wednesday, 26 November 2008
Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary liver cancer treatment for melanoma metastatic to the liver, announced today that the United States Food and Drug Administration (“FDA”) granted to Delcath two orphan-drug applications for the drug melphalan. Delcath was granted designations of the drug melphalan for the treatment of patients with cutaneous as well as ocular melanoma. Approximately 65,000 cases of these melanomas are diagnosed annually in the United States alone.

Delcath is actively enrolling patients in a Phase III clinical trial testing its proprietary drug delivery system, known as Percutaneous Hepatic Perfusion (“PHP”), with melphalan for the treatment of ocular and cutaneous melanoma metastatic to the liver. This NCI-led trial is enrolling patients at leading cancer centers throughout the United States. Commenting on these orphan-drug designations, Richard L. Taney, President and CEO of Delcath, stated, “These favorable designations are important steps in our efforts to secure Delcath’s commercial position upon conclusion of our pivotal Phase III trial for metastatic melanoma. We remain steadfast in our commitment to become the leader in the regional treatment of liver cancers and we continue to enroll patients in this study, and advance our technology and the promise that it offers to patients with these deadly forms of melanoma and other cancers of the liver, all with limited treatment options.”

Orphan drug designation, when granted by the FDA’s Office of Orphan Products Development, allows for up to seven years of market exclusivity upon FDA approval, as well as clinical study incentives, study design assistance, waivers of certain FDA user fees, and potential tax credits.
N3L Introduces Interactive Retail Technology in New Bay Area Store PDF
Submit Your News
International News
Tuesday, 25 November 2008
Luxottica owned N3L Optics recently announced the grand opening of its sport performance sunglass store at Hillsdale Mall in San Mateo, CA, US. N3L Optics takes an innovative approach with the use of technology to simulate real life conditions in the store--offering customers the ability to experience the benefits of the latest in high-performance eyewear and select the perfect match for their active lifestyles.

Designed with the athlete, sports and outdoor enthusiast in mind, N3L Optics is a destination stop for anyone interested in improving performance and overall experience with the right choice in sport sunglasses. N3L delivers a unique customer experience with innovative stations such as:

N3L Smart Mirror--Using RFID technology, N3L's "Smart Mirror" (see picture) identifies the frames that a customer is wearing and displays key features and specifications for each selection. Customers can also use the N3L Smart Mirror to take a photo and email friends and family their choice for new eyewear.

Newton Immersive Display--N3L's touch screen display teaches customers about the features and product specifications from leading manufacturers of sport performance eyewear.

Explorer Chamber--N3L's Explorer Chamber is an environmental simulator where customers can test frames and lenses under varying light and airflow conditions and measure the effects of up to 65 mph winds.

N3L Custom Fit Station--N3L's highly trained staff will help customers build their own custom sunglasses or goggles and will also ensure chosen eyewear is uniquely fit to the customer's lifestyle.
Therapeutic Potential for Human Cationic Amino Acid Transporters PDF
Submit Your News
Ophthalmology and Optometry
Monday, 24 November 2008
German scientists conducted a study to evaluate the presence and role of human cationic amino acid transporters (hCATs) at the ocular surface in healthy and pathologic states and under experimental inflammatory conditions. Their results show for the first time the distribution of hCATs in tissues of the ocular surface and lacrimal apparatus.

They analyzed the expression of mRNA for hCATs 1, 2 and 3 (SLC7A1, -A2 and –A3) by RT-PCR in healthy lacrimal gland, conjunctiva, cornea and nasolacrimal ducts as well as in a SV40 immortalized corneal epithelial cell line and determined localization of hCAT1 and hCAT2 by immunohistochemistry in healthy tissues and in sections of different corneal pathologies including keratoconus, Fuchs' dystrophy and herpetic keratitis. The scientists stimulated cultured corneal epithelial cells with proinflammatory cytokines and supernatants of Staphylococcus aureus and Pseudomonas aeruginosa and analyzed these by real-time PCR.

They detected the expression of both hCAT1 and hCAT2 mRNA in healthy conjunctiva, cornea and nasolacrimal ducts, but not of hCAT3 mRNA. Human lacrimal gland revealed only hCAT2 mRNA expression and immunohistochemistry demonstrated presence of both hCAT1 and hCAT2 in epithelial cells of cornea, conjunctiva and nasolacrimal ducts. Additionally, goblet cells revealed no reactivity and hCAT2 was visible in acinar cells of lacrimal gland. While no changes in the staining reactivity were obtained for hCAT1 in different corneal pathologies, hCAT2 showed increased subjective staining intensity in all corneal pathologies.

The scientists found that hCAT1 and hCAT2 seem to be differently regulated under pathological conditions of the ocular surface and that their physiological functions in amino acid transport make them potential candidates for therapeutic intervention in ocular surface disease.
Northern Territory - The Visual Spectacle PDF
Submit Your News
Australian News
Monday, 24 November 2008
More than 300 million people, worldwide are blind or vision impaired because they don’t have access to the type of eye care provided by Dorothy Butler, in the Northern Territory of Australia, according to Professor Brien Holden, CEO of ICEE.

Dorothy (Dot) Butler is the Regional Eye Health Coordinator for Wurli Wurlinjang Health Service, an Aboriginal Medical Service (AMS) in Katherine.

In between visits to communities in her care and general health care duties, she manages the busy list of referrals to visiting ICEE Optometrists as well as local Ophthalmologists.

Dot’s role as Regional Eye Health Coordinator covers an area from Katherine in the north to Lajamanu in the south and east to Borroloola, an area larger than some European countries.

Dot is a warm, generous character and, like so many health care workers, when you scratch the surface you find an ambitious, hard working woman dedicated to good eye care and healthy vision for the Indigenous people of her communities.

Robyn (pictured) hadn’t visited the Eye Clinic at Wurli, as its known locally, for an eye examination until recently when she met ICEE Optometrist, Tricia Keys. After a car accident that lead to the removal of her left eye in 2004, further damage in her right eye, has left Robyn close to blind.

On examination Tricia discovered, through a strong lens in a trial frame used to assess Robyn’s prescription, the vision in her right eye could be improved allowing her to see well for the first time in years.

Brien Holden is less known at home in Australia than he is internationally where he is renowned for his contribution to public health and vision correction research. He works exhaustively on the issue of global eye care but worries that the problem of unnecessary vision impairment and blindness due to refractive error is a burgeoning global health crisis.

“We talk about 300 million people, but the number doesn’t include those suffering from presbyopia. If we were to include that number, then uncorrected refractive error (URE) would be considered one the biggest health care challenges facing us today,” he said.

“The reality is that as we age our eyes begin to deteriorate, a condition known as presbyopia. It affects most of us over by the age of 45 years. Usually, a pair of glasses is all that is needed to correct the problem.”

“It’s an established fact - visual impairment has a direct link with poverty,” said Prof Holden.

In developing and remote communities around the world, getting access to eye care is often difficult and not always because of the cost involved. “To get an eye examination it can involve travelling long distances and leaving work and family to get there.”

“There is a long list of other deterrents that prevent millions worldwide from getting access to an eye examination and the right pair of glasses, but not addressing a vision problem can have devastating consequences.”

“That’s why the work of Dot Butler at Wurli Wurlinjang Health Service is so important,” he added.
<< Start < Prev 221 222 223 224 225 226 227 228 229 230 Next > End >>

Page 224 of 304